Literature DB >> 24847891

Breast cancer and aging: results of the U13 conference breast cancer panel.

M F Barginear1, H Muss, G Kimmick, C Owusu, E Mrozek, A Shahrokni, K Ballman, A Hurria.   

Abstract

Breast cancer is predominantly a disease of older women, yet there is a knowledge gap due to the persisting misalignment between the age distribution of women with breast cancer and the age distribution of participants in clinical trials. The purpose of this report is to state the U13 conference breast cancer panel's recommendations regarding therapeutic clinical trials that will fill gaps in knowledge regarding the care of older patients with breast cancer. The U13 conference was a collaboration between the Cancer and Aging Research Group and the National Institute on Aging and the National Cancer Institute (NCI). Clinical trials should be developed for frail and vulnerable patients who would not enroll on the standard phase III trials, as well as efforts need to be made to increase enrollment of fit older patients on standard phase III trials. As a result of this conference, panel members are working with the NCI and cooperative groups to address these knowledge gaps. With the aging population and increasing incidence of breast cancer with age, it is essential to study the feasibility, toxicity, and efficacy of cancer therapy in this at-risk population.

Entities:  

Mesh:

Year:  2014        PMID: 24847891      PMCID: PMC4077335          DOI: 10.1007/s10549-014-2994-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  26 in total

1.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Authors:  Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves
Journal:  Lancet       Date:  2011-03-02       Impact factor: 79.321

2.  The burden of neuropathic pain: results from a cross-sectional survey.

Authors:  Anne M McDermott; Thomas R Toelle; David J Rowbotham; Caroline P Schaefer; Ellen M Dukes
Journal:  Eur J Pain       Date:  2006-02       Impact factor: 3.931

3.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

Review 4.  International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.

Authors:  Stuart M Lichtman; Hans Wildiers; Etienne Chatelut; Christopher Steer; Daniel Budman; Vicki A Morrison; Brigitte Tranchand; Iuliana Shapira; Matti Aapro
Journal:  J Clin Oncol       Date:  2007-05-10       Impact factor: 44.544

5.  Future of cancer incidence in the United States: burdens upon an aging, changing nation.

Authors:  Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2009-04-29       Impact factor: 44.544

6.  Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

Authors:  Eva S Thomas; Henry L Gomez; Rubi K Li; Hyun-Cheol Chung; Luis E Fein; Valorie F Chan; Jacek Jassem; Xavier B Pivot; Judith V Klimovsky; Fernando Hurtado de Mendoza; Binghe Xu; Mario Campone; Guillermo L Lerzo; Ronald A Peck; Pralay Mukhopadhyay; Linda T Vahdat; Henri H Roché
Journal:  J Clin Oncol       Date:  2007-10-29       Impact factor: 44.544

7.  Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.

Authors:  Mary C Pinder; Zhigang Duan; James S Goodwin; Gabriel N Hortobagyi; Sharon H Giordano
Journal:  J Clin Oncol       Date:  2007-07-30       Impact factor: 44.544

8.  Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.

Authors:  Craig Bunnell; Linda Vahdat; Lee Schwartzberg; Julie Gralow; Judith Klimovsky; Valerie Poulart; Ronald Peck; Eva Thomas
Journal:  Clin Breast Cancer       Date:  2008-06       Impact factor: 3.225

9.  Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.

Authors:  Lee S Schwartzberg; Lee S Schwarzberg; Sandra X Franco; Allison Florance; Lisa O'Rourke; Julie Maltzman; Stephen Johnston
Journal:  Oncologist       Date:  2010-02-15

10.  Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older.

Authors:  Margaret McDonald; Robin P Hertz; Alan N Unger; Michael B Lustik
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-01-30       Impact factor: 6.053

View more
  5 in total

1.  AMP hydrolysis reduction in blood plasma of breast cancer elderly patients after different treatments.

Authors:  Fernanda Valente Gheler; Angélica Regina Cappellari; Daiana Renck; Julia Brandt de Souza; Renan Oliveira de Melo; Barbara Zanesco Moehlecke; Carolina Aiko Moriguchi; Paula Engroff; Ana Paula Franco Lambert; Liliana Rockenbach; Fernanda Bueno Morrone
Journal:  Mol Cell Biochem       Date:  2021-06-05       Impact factor: 3.396

Review 2.  Manganese Superoxide Dismutase Acetylation and Dysregulation, Due to Loss of SIRT3 Activity, Promote a Luminal B-Like Breast Carcinogenic-Permissive Phenotype.

Authors:  Xianghui Zou; Cesar Augusto Santa-Maria; Joseph O'Brien; David Gius; Yueming Zhu
Journal:  Antioxid Redox Signal       Date:  2016-04-15       Impact factor: 8.401

3.  Exploring and supporting older women's chemotherapy decision-making in early-stage breast cancer.

Authors:  Meghan S Karuturi; Sharon H Giordano; Diana S Hoover; Robert J Volk; Ashley J Housten
Journal:  J Geriatr Oncol       Date:  2021-12-23       Impact factor: 3.929

4.  Could Anthropometric and Lipid Parameters Reflect Susceptibility to Breast Cancer? Comparison of Newly Diagnosed Breast Cancer and Apparently Healthy Women

Authors:  H M K Akalanka; S Ekanayake; K Samarasinghe
Journal:  Asian Pac J Cancer Prev       Date:  2018-09-26

5.  Alterations in Immune-Related Genes as Potential Marker of Prognosis in Breast Cancer.

Authors:  Bei Li; Rongxin Geng; Qi Wu; Qian Yang; Si Sun; Shan Zhu; Zhiliang Xu; Shengrong Sun
Journal:  Front Oncol       Date:  2020-03-12       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.